Windtree Therapeutics, Inc. (WINT)

NASDAQ: WINT · IEX Real-Time Price · USD
0.398
+0.009 (2.29%)
Aug 12, 2022 11:20 AM EDT - Market open
2.29%
Market Cap 11.70M
Revenue (ttm) n/a
Net Income (ttm) -66.80M
Shares Out 29.41M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 86,763
Open 0.425
Previous Close 0.389
Day's Range 0.381 - 0.425
52-Week Range 0.350 - 2.370
Beta 0.31
Analysts Buy
Price Target 3.47 (+772.3%)
Earnings Date Aug 8, 2022

About WINT

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress s... [Read more...]

Industry Biotechnology
IPO Date Aug 8, 1995
Employees 33
Stock Exchange NASDAQ
Ticker Symbol WINT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for WINT stock is "Buy." The 12-month stock price forecast is 3.47, which is an increase of 772.30% from the latest price.

Price Target
$3.47
(772.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular a...

Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discuss...

Positive Data for Istaroxime in Early Cardiogenic Shock

Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Bre...

The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also persis...

Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Car...

Call to be held on Monday, May 23rd at 4:30 pm EDT following the Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting Call to be held on Monday, May 23rd at 4:30 pm EDT ...

Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates

Announced positive topline results from Phase 2  SEISMiC study of istaroxime in early cardiogenic shock

Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Car...

Company to host conference call following the presentation Company to host conference call following the presentation

Windtree Therapeutics Stock Is Trading Higher: Here's Why

Windtree Therapeutics Inc (NASDAQ: WINT) shares are trading higher Wednesday after the company announced topline results from the Phase 2 SEISMiC study of istaroxime in early cardiogenic shock. Istaroxi...

Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic Shock

Istaroxime significantly improved the systolic blood pressure profile Istaroxime significantly improved the systolic blood pressure profile

Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference

Company to present on Monday, April 4, 2022 at 11:00 am Company to present on Monday, April 4, 2022 at 11:00 am

Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular ...

Windtree Posts Mid-Stage Study Data On Lucinactant For COVID-19-Associated Respiratory Distress

Windtree Therapeutics Inc (NASDAQ: WINT) announced results from its Phase 2 study of lucinactant (KL4 surfactant) for severe COVID-19 associated acute respiratory distress syndrome (ARDS) and lung injur...

Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress S...

Results support the feasibility for development of a potential treatment for critically ill patients with ARDS due to COVID-19 and other causes Results support the feasibility for development of a poten...

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

On track for top-line data in April 2022 On track for top-line data in April 2022

Windtree to Present at Oppenheimer's 32nd Annual Healthcare Conference

WARRINGTON, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for ac...

Why Are Windtree Therapeutics Shares Trading Higher Today?

Windtree Therapeutics Inc WINT has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Data is anticipated in Q1 ...

Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injur...

Data anticipated in first quarter 2022 Data anticipated in first quarter 2022

Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent

New Patent Provides Intellectual Property Protection Through Late 2039 New Patent Provides Intellectual Property Protection Through Late 2039

2 Moonshot Biotechs with 10x Potential

This strategy identified LGVN stock a month ago, and now its price has skyrocketed. Here are two more biotechs that could do the same.

Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay – Addin...

Windtree Is Studying Istaroxime in Early Cardiogenic Shock Patients Windtree Is Studying Istaroxime in Early Cardiogenic Shock Patients

Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular a...

3 Moonshot Stocks Insiders Are Buying… and 2 That Are Getting Dumped

Insiders often know things the general public doesn't yet, which means that an otherwise unexciting company with insider trades can be great. The post 3 Moonshot Stocks Insiders Are Buying… and 2 That A...

Other symbols: DWACVLCNBYRN

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

Anticipated New Patent Will Provide Intellectual Property Protection Until Late 2039 Anticipated New Patent Will Provide Intellectual Property Protection Until Late 2039

Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming D...

Tuesday, October 19th @ 8:00 am Eastern Time Tuesday, October 19th @ 8:00 am Eastern Time

Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Trea...

Cardiogenic Shock Worldwide Total Market Value Is Estimated To Be $1.25 Billion Cardiogenic Shock Worldwide Total Market Value Is Estimated To Be $1.25 Billion

Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

WARRINGTON, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for ac...